ICON Public (NASDAQ:ICLR) Receives Outperform Rating from William Blair

ICON Public (NASDAQ:ICLR)‘s stock had its “outperform” rating reissued by William Blair in a research note issued on Tuesday,Benzinga reports.

A number of other brokerages have also recently commented on ICLR. Leerink Partners reiterated an “outperform” rating and set a $255.00 price target (down from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. JPMorgan Chase & Co. decreased their target price on shares of ICON Public from $375.00 to $280.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Leerink Partnrs upgraded shares of ICON Public to a “strong-buy” rating in a research report on Wednesday, September 18th. Robert W. Baird decreased their price objective on ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a report on Wednesday, November 20th. Finally, The Goldman Sachs Group lowered their target price on ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $287.00.

ICON Public Price Performance

Shares of NASDAQ:ICLR opened at $199.47 on Tuesday. ICON Public has a one year low of $183.38 and a one year high of $347.72. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. The firm has a market capitalization of $16.46 billion, a price-to-earnings ratio of 22.24, a PEG ratio of 1.54 and a beta of 1.20. The company’s fifty day moving average price is $210.79 and its 200-day moving average price is $270.01.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter in the previous year, the business earned $3.10 EPS. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, equities research analysts anticipate that ICON Public will post 13.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ICON Public

Several institutional investors and hedge funds have recently modified their holdings of ICLR. GAMMA Investing LLC raised its stake in ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after buying an additional 169 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of ICON Public by 39.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock worth $129,000 after acquiring an additional 111 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its stake in shares of ICON Public by 23.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock valued at $147,000 after purchasing an additional 96 shares during the period. First Horizon Advisors Inc. boosted its position in shares of ICON Public by 33.9% during the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 151 shares in the last quarter. Finally, Steph & Co. grew its stake in ICON Public by 3.7% in the fourth quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock worth $327,000 after purchasing an additional 55 shares during the period. 95.61% of the stock is owned by hedge funds and other institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.